Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion [PDF]
Mov Disord Clin PractMovement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley +2 more sources
Continuous Subcutaneous Apomorphine as a Temporary Bridging Therapy for Dopamine Dysregulation Syndrome in Patients with Deep Brain Stimulation [PDF]
Movement Disorders Clinical Practice, EarlyView.Abstract Background Dopamine dysregulation syndrome (DDS) is a challenging complication of dopaminergic therapy in Parkinson's disease and can persist despite subthalamic deep brain stimulation (STN‐DBS). We evaluated a temporary bridging concept in which oral dopaminergic medication was replaced by continuous subcutaneous apomorphine infusion while ...
Tobias Binder +8 more
wiley +2 more sources
Stability of apomorphine in solutions containing selected antioxidant agents [PDF]
Drug Design, Development and Therapy, 2016 Zen Yang Ang, Michael Boddy, Yandi Liu, Bruce Sunderland School of Pharmacy, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia Abstract: Apomorphine in solution undergoes rapid autoxidation, producing greenish colored solutions ...
Ang ZY, Boddy M, Liu Y, Sunderland B
doaj +2 more sources
Genotoxic, neurotoxic and neuroprotective activities of apomorphine and its oxidized derivative 8-oxo-apomorphine [PDF]
Brazilian Journal of Medical and Biological Research, 2005 Apomorphine is a dopamine receptor agonist proposed to be a neuroprotective agent in the treatment of patients with Parkinson's disease. Both in vivo and in vitro studies have shown that apomorphine displays both antioxidant and pro-oxidant actions, and ...
J.N. Picada +2 more
doaj +4 more sources
Turmeric active substance, curcumin, enhanced apomorphine-induced yawning in rats [PDF]
Avicenna Journal of Phytomedicine, 2013 Objective: Curcumin is a major constituent of turmeric and influences many functions of the brain. In the present study, we investigated the effect of curcumin on yawning induced by apomorphine in rats.
Esmaeal Tamaddonfard
doaj +1 more source
Apomorphine effects on the hippocampus [PDF]
Neural Regeneration Research, 2018 Apomorphine is a non-specific dopamine receptor agonist that has been used in the treatment of some diseases and mental disorders. Its use has particularly well documented in Parkinson's disease (PD).
Luis Enrique Arroyo-Garcia +2 more
doaj +2 more sources
Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort [PDF]
Movement Disorders Clinical Practice, EarlyView.Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy +16 more
wiley +2 more sources
Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients [PDF]
Clinical and Translational ScienceApomorphine, used to treat OFF episodes in patients with Parkinson's disease (PD), is typically administered via subcutaneous injections. Administration of an oromucosal solution could offer a non‐invasive and user‐friendly alternative.
Eva Thijssen +8 more
doaj +2 more sources
Identification of the efficacy and safety of apomorphine in the treatment of Parkinson’s disease via meta-analysis [PDF]
BMC NeurologyBackground The majority of Parkinson’s disease (PD) patients experience motor fluctuations and dyskinesias as the disease progresses. Apomorphine has been used as an acute treatment for off episodes in PD in recent years.
Haidong Li +3 more
doaj +2 more sources
Nose-to-Brain Therapeutics in Parkinson’s Disease: Clinical Trials, Mechanisms, and Therapeutic Potential [PDF]
PharmaceuticsBackground/Objectives: Intranasal delivery is a promising noninvasive approach to enhance central nervous system drug delivery in Parkinson’s disease (PD), potentially bypassing the blood–brain barrier and minimizing gastrointestinal side effects.
Emily Cherny, Tamara Minko
doaj +2 more sources